This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Aziz, M. H. Articles by Ahmad, N. Search for Related Content PubMed PubMed Citation Articles by Aziz, M. H. Articles by Ahmad, N.

Research Articles: Therapeutics

Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins

Departments of ¹ Dermatology and ² Surgery, University of Wisconsin, Madison, Wisconsin

Requests for reprints: Nihal Ahmad, Department of Dermatology, University of Wisconsin, 1300 University Avenue, Medical Science Center B-25, Madison, WI 53706. Phone: 608-263-5359; Fax: 608-263-5223. E-mail: nahmad{at}wisc.edu

Prostate cancer is a major health problem in the U.S. and the available treatment and surgical options have proven to be inadequate in controlling the mortality and morbidity associated with this disease. It is therefore necessary to intensify our efforts to better understand this disease and develop novel approaches for its prevention and treatment. This study was conducted to evaluate the chemopreventive/antiproliferative potential of resveratrol (trans-3,4',5,-trihydroxystilbene) against prostate cancer and its mechanism of action. Treatment with resveratrol (0–50 µmol/L for 24 hours) resulted in a significant (a) decrease in cell viability, (b) decrease of clonogenic cell survival, (c) inhibition of androgen (R1881)-stimulated growth, and (d) induction of apoptosis in androgen-responsive human prostate carcinoma (LNCaP) cells. Interestingly, at similar concentrations, resveratrol treatment did not affect the viability or rate of apoptosis in normal human prostate epithelial cells. Furthermore, our data showed that resveratrol-treatment resulted in significant dose-dependent inhibition in the constitutive expression of phosphatidylinositol 3'-kinase and phosphorylated (active) Akt in LNCaP cells. Resveratrol treatment for LNCaP cells was also found to result in a significant (a) loss of mitochondrial membrane potential, (b) inhibition in the protein level of antiapoptotic Bcl-2, and (c) increase in proapoptotic members of the Bcl-2 family, i.e., Bax, Bak, Bid, and Bad. Taken together, our data suggested that resveratrol causes an inhibition of phosphatidylinositol 3'-kinase/Akt activation that, in turn, results in modulations in Bcl-2 family proteins in such a way that the apoptosis of LNCaP cells is promoted. Based on these studies, we suggest that resveratrol could be developed as an agent for the management of prostate cancer. [Mol Cancer Ther 2006;5(5):1335–41]

Received 12/15/05; revised 3/ 7/06; accepted 3/24/06.

This article has been cited by other articles:

				C. E. Harper, B. B. Patel, J. Wang, A. Arabshahi, I. A. Eltoum, and C. A. Lamartiniere Resveratrol suppresses prostate cancer progression in transgenic mice Carcinogenesis, September 1, 2007; 28(9): 1946 - 1953. [Abstract] [Full Text] [PDF]

				Y. Dai, D. Ngo, L. W. Forman, D. C. Qin, J. Jacob, and D. V. Faller Sirtuin 1 Is Required for Antagonist-Induced Transcriptional Repression of Androgen-Responsive Genes by the Androgen Receptor Mol. Endocrinol., August 1, 2007; 21(8): 1807 - 1821. [Abstract] [Full Text] [PDF]

				J.-L. Su, C.-Y. Yang, M. Zhao, M.-L. Kuo, and M.-L. Yen Forkhead Proteins Are Critical for Bone Morphogenetic Protein-2 Regulation and Anti-tumor Activity of Resveratrol J. Biol. Chem., July 6, 2007; 282(27): 19385 - 19398. [Abstract] [Full Text] [PDF]

				D. A. Benitez, E. Pozo-Guisado, A. Alvarez-Barrientos, P. M. Fernandez-Salguero, and E. A. Castellon Mechanisms Involved in Resveratrol-Induced Apoptosis and Cell Cycle Arrest in Prostate Cancer-Derived Cell Lines J Androl, March 1, 2007; 28(2): 282 - 293. [Abstract] [Full Text] [PDF]